HOME >> BIOLOGY >> NEWS
Rutgers-led research offers new clues in the genetic mysteries of maize

NEW BRUNSWICK/PISCATAWAY, N.J. Rutgers researchers, with the support of the National Science Foundation, have pushed back the frontiers on the genetic nature and history one of the world's most important crops corn. This crop dominates agriculture in the United States, where approximately 9 billion bushels are produced annually at a value of $30 billion. Maize (or corn) is also an important dietary staple in much of the third world.

Rutgers' Joachim Messing and his colleagues announced this month discoveries about the inner workings of corn, its origins and evolution, with implications for breeding, genetic engineering and future genomic studies.

"This latest research, conducted with worldwide collaborations, led us to a new understanding of maize that will help enable scientists and farmers to make major improvements in one of the world's most significant crops and gain new and important insights in plant genomic studies," said Messing, director of the Waksman Institute of Microbiology at Rutgers, The State University of New Jersey. The findings are presented in three papers in the journal Genome Research and one in the Proceedings of the National Academy of Sciences.

The scientists conducted the most comprehensive survey of the maize genome ever performed and established for the first time the genome's magnitude approximately 59,000 genes and the relative position of the genes. This is twice as many as the human genome and the highest number of genes of any genome sequenced to date. Messing emphasized that this survey is only a first step and conducting a whole genome sequence is a priority dictated by nutritional, economic and societal needs.

The research further established that in addition to its immense size, the corn genome is extremely complex due, in part, to positional instability as well as its genetic history. Messing and his colleagues concluded that maize genes are scrambled, having moved around to different locat
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
12-Oct-2004


Page: 1 2

Related biology news :

1. Rutgers-led group lands $2.55 million to advance high school biology and math
2. National Science Foundation awards $15 million grant to Rutgers-led engineering research consortium
3. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
4. Saudi Arabias KAUST names WHOI first research partner
5. Multinational research: protecting ecology means understanding people, too
6. Newly created cancer stem cells could aid breast cancer research
7. Carnegie Mellons Peter Adams receives EPA research grant
8. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
9. Innovative tagging technique may help researchers better protect fish stocks
10. Penn researchers discover how key protein stops inflammation
11. UCF research links proteins, stem cells and potential Alzheimers treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rutgers led research offers new clues the genetic mysteries maize

(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: